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Abstract
Friedreich’s ataxia is an autosomal recessive disorder characterized by impaired mitochon-
drial function, resulting in oxidative stress. In this study, we aimed at evaluating whether
tocotrienol, a phytonutrient that diffuses easily in tissues with saturated fatty layers, could
complement the current treatment with idebenone, a quinone analogue with antioxidant
properties. Five young Friedreich’s ataxia patients received a low-dose tocotrienol supple-
mentation (5mg/kg/day), while not discontinuing idebenone treatment. Several oxidative
stress markers and biological parameters related to oxidative stress were evaluated at the
time of initiation of treatment and 2 and 12 months post-treatment. Some oxidative stress-
related parameters and some inflammation indices were altered in Friedreich’s ataxia
patients taking idebenone alone and tended to be normal values following tocotrienol sup-
plementation; likewise, a cardiac magnetic resonance study showed some improvement
following one-year tocotrienol treatment. The pathway by which tocotrienol affects the Nrf2
modulation of hepcidin gene expression, a peptide involved in iron handling and in inflam-
matory responses, is viewed in the light of the disruption of the iron intracellular distribution
and of the Nrf2 anergy characterizing Friedreich’s ataxia. This research provides a suitable
model to analyze the efficacy of therapeutic strategies able to counteract the excess free radicals in Friedreich’s ataxia, and paves
the way to long-term clinical studies.
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Introduction
Friedreich’s ataxia (FRDA, OMIM #229300) is a hereditary
ataxia, with a clinical onset around puberty. It is an autoso-
mal recessive disease causing the degenerative atrophy
of the posterior columns of the spinal cord and leading
to progressive neurologic disability, sensory loss, and
muscle weakness. Hypertrophic cardiomyopathy is rather
common, affecting 45–63% of FRDA patients and can cause
Impact statement
Oxidative stress is involved in the patho-
genesis of Friedreich’s ataxia (FRDA), a
genetic disorder causing neurodegenera-
tion due to the dramatic reduction in the
expression of frataxin. To date, no cure is
available for FRDA patients. In some
countries, FRDA patients assume idebe-
none in order to counteract the effects of
frataxin deficiency. We demonstrate that
idebenone treatment alone is not able to
abrogate oxidative stress in FRDA patients,
whereas the combined treatment with
tocotrienols might be more efficient and
perhaps produce clinical improvement. In
fact, a decrease in oxidative stress and
inflammation markers can be seen after
two months and is more pronounced after
one year of treatment. This is, in our opin-
ion, valuable information for clinicians,
since idebenone is the treatment of choice
for FRDA patients in some countries.
ISSN 1535-3702 Experimental Biology and Medicine 2020; 245: 201–212
Copyright ! 2019 by the Society for Experimental Biology and Medicine
premature death. In some patients, diabetes mellitus, sco-
liosis, and foot deformity are also observed.1,2
FRDA is caused by the partial deficiency of frataxin, a
210-amino acid protein, which localizes in the mitochon-
dria. Most patients are homozygous for an unstable GAA
trinucleotide expansion in the first intron of the gene, FXN,
located on chromosome 9q13.3 The expanded GAA repeats
cause a decrease in transcription, owing to an abnormal
chromatin conformation. Frataxin function is somewhat
unclear, although there is general agreement that it
is involved in cellular iron homeostasis; in particular,
it participates in the mitochondrial synthesis of iron–
sulfur-containing proteins and in heme synthesis.4 Its defi-
ciency leads to multiple enzyme deficits, mitochondrial
dysfunction, deficit of ATP production and oxidative
damage.5–7 In addition, in vitro studies with Schwann cell
lines which underwent FXN knockdown8 showed that fra-
taxin deficiency causes a strong activation of inflammatory
pathways. Numerous studies have pointed out a hypersen-
sitivity to oxidative stress (OS) in cell models and FRDA
patients and the presence of some oxidation biomarkers in
urine and blood samples from FRDA patients.9–13 OS is a
major cause of neuron degeneration and death, although it
is unclear whether, in FRDA patients’ cells, OS is a conse-
quence of the observed iron accumulation in mitochondria,
coupled to an iron cytoplasmic depletion (for an in-depth
discussion, see reviews14,15). Some authors have suggested
that frataxin deficiency is linked to oxidative stress condi-
tion mainly because Nrf2-driven responses appear to be
impaired.16 In addition, altered lipid metabolism is consid-
ered a hallmark of FRDA pathophysiology. The mechanisms
by which the lipid metabolism is impaired in FRDA remain
uncertain. It has been suggested that frataxin deficiency and
the consequent dysfunction of the mitochondrial respiratory
chain lead to the alteration of main pathways involved in
fatty acid synthesis and degradation.17
Based upon these considerations, we suggest that FRDA
patients might benefit of treatment with antioxidants.
Italian FRDA patients are currently treated with idebenone,
a short chain quinone analogue, which acts as a free-radical
scavenger; the rationale for treatment is based on the con-
sideration that mitochondrial energy shortage and oxida-
tive stress are critical factors for FRDA in neuronal cells.18,19
Notwithstanding the therapeutic benefits of idebenone in
improving neurological functions20 and in the prevention
of cardiopathy,21 patients still experience a progressivewors-
ening of their condition. The present study was devised in
order to understand whether idebenone is effective in abat-
ing OS and whether patients might better benefit of a com-
bined therapy with another antioxidant, tocotrienol.
Tocotrienols are natural forms of vitamin E, which are
found in several natural sources, including coconut oil, palm
oil, rice bran oil, cocoa butter, barley, and wheat germ.22
Tocotrienols, as compared to tocopherols, are characterized
by three double bonds. Such small difference, involving six
hydrogen atoms, confers to tocotrienols the ability to diffuse
in tissues with high lipid content22,23 and improves their
anticancer, antioxidant, cardioprotective and neuroprotec-
tive activities, both in vitro and in vivo.24,25 Tocotrienols
have quite different behavior as compared to tocopherols:
a specific metabolism and specific routes of tissue delivery
and storage,26 and the “chain-breaking” ability to neutralize
peroxyl radicals through the formation of phenoxyl radicals,
which are relatively stable. Tocotrienols also decrease
oxidative-nitrosative stress and the inflammatory cascade
in experimental models of alcoholic and diabetic neuropa-
thy.24 Noteworthy, tocotrienols lead to a specific and signif-
icant increase in FXN-3 expression. In FRDA patients, this
protein is a minor, functionally active, FXN isoform.27
Tocotrienols increase, in vitro, transcription of IKBKAP
gene, mutated in the neurodegenerative genetic disorder
Familial dysautonomia, leading to an increase in the correct-
ly spliced transcript and normal protein.28 Moreover, toco-
trienols possess in vitro antifibrotic properties,29 and,
recently, Yang et al. elucidated the mechanisms by which
d-Tocotrienol reduces inflammation through the inhibition
of TNF-a-induced activation of NF-jB and the LPS-
stimulated IL-630 expression. Finally, tocotrienols are able
to modulate the sensitivity to ferroptosis by inhibiting lipid
peroxidation.31 Ferroptosis is a form of regulated iron-
dependent cell death, recently identified in FRDA
fibroblasts.32
Recently, EPI-743 (alpha-tocotrienol quinone; vatiquinone),
a last-generation tocotrienol variant, was tested in FRDA
patients and found to improve neurological and disease pro-
gression parameters following a 24-month treatment.33
Here we report data from a pilot study carried out with
five FRDA patients, taking idebenone and a tocotrienol mix-
ture (5mg/kg/day) for one year, where biomarkers related
to OS were compared with data obtained from age- and sex-
matched healthy controls. Patients’ blood samples were col-
lected for the initiation of treatment and 2 and 12 months of
post-treatment; however, due to a freezer failure, some bio-
logical evaluations could not be carried out for the 12-month
treatment. Patients were also studied by conventional and
advanced cardiac magnetic resonance (CMR) techniques,
including a CMR cardiac study, completed by gadolinium
perfusion late enhancement evaluation.34 Improvements
observed in OS biomarkers and, to a lesser extent, in clinical
outcomes suggested that adjunctive treatment with tocotrie-
nols might be worthy of a study on a wider scale.
Materials and methods
Patients and treatment
Seven FRDA patients and seven healthy volunteers of sim-
ilar age were enrolled by the Child Neurology and
Psychiatry Unit of the IRCCS Istituto delle Scienze
Neurologiche of Bologna. FRDA diagnosis was performed
according to Harding diagnostic criteria35 and confirmed
by genetic testing, which showed that all FRDA patients
were homozygous for GAA triplet expansion in the FXN
gene. The level of clinical disability was quantified accord-
ing to ICARS scale.36 Data are summarized in Table 1.
All patients were treated with idebenone (5mg/kg body
weight/day) throughout the study. FRDA patients 1–5
shown in Table 1 assumed tocotrienol (5mg/kg body
weight/day) for 12 months. A venous blood sample was
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obtained before the initiation of tocotrienol (FRDA), follow-
ing twomonths (FRDA post-2months) and following the
full term of treatment (FRDA post-1 year). Biomarkers
were compared in seven age-and-sex-matched healthy con-
trol subjects (CTR). Controls were devoid of any clinical
sign of psychiatric or neurological diseases and did not
take antioxidant and/or vitamin supplements or medica-
tions potentially affecting oxidative status. The Local
Ethical Committee approved the study (1635– 08092011).
At the beginning of the study and following one year of
treatment with tocotrienols, patients were evaluated
according to the ICARS scale and assessed with conven-
tional cerebral magnetic resonance imaging (MRI), MRI
study of cerebral protons (1HMRS), muscle phosphorus
spectroscopy study (31PMRS), diffusion-weighted imaging
(DWI), diffusion tensor imaging (DTI), and CMR imaging.
For details, please see Fortuna.34
Tocotrienol
The toxicity level of tocotrienols for humans is presently
undetermined; however, they are deemed to be safe as for
long-term use in nutrition. According to Nakamura et al.,37
the estimated no-observed-adverse-effect level (NOAEL) in
rats is 120–130mg/kg body weight/day, while Tasaki et al.38
report higher values (303mg/kg/day for males, and
472mg/kg bodyweight/day for females). No adverse effects
were reported in humans administered with 240mg/kg
body weight/day tocotrienols for 18–24months.39 The
dose administered in the present study was 5mg/kg
body weight/day, i.e. well below that reported by Tomeo
et al.39 Moreover, it was demonstrated by Patel et al.40 that
400mg/day of tocotrienol oral supplementation, a dose sim-
ilar to the one used in this study, was sufficient to detect the
presence of tocotrienol isoforms in blood, heart, and brain
after 80days, 155days (range 30–443), and 261days (range
78–672days), respectively.
The tocotrienol mixture was developed by Ambrosialab
s.r.l., a spin-off company of the Ferrara University, Italy.
The tocotrienol mixture, consisting of a Palm Oil (Elaeis
Guineensis) phytocomplex, is formulated as soft gel cap-
sule “OXI-3” (internal ref. name ALAB103). Its composition
is reported in Table 2. Dose, composition of tocotrienol mix,
time of treatment used in this study were in the same
ranges as those reported in Patel et al.40
Blood sample treatment
Fifteen milliliters of blood were drawn and collected in a
test tube containing EDTA. An aliquot of whole blood
(1mL) was used for lipidomic analysis; the remaining
part was used to obtain the blood components. Following
centrifugation of blood at 1000 g for 10min, plasma was
retrieved and stored at 20C for subsequent use.
Peripheral blood mononuclear cells (PBMCs) and erythro-
cytes were obtained by density gradient centrifugation
with Ficoll (Histopaque 1077, Sigma-Aldrich, St.Louis,
Mo) after dilution (1:1) with sterile phosphate-buffered
saline (PBS). PBMCs were collected, lysed in 1mL TrizolVR
Reagent (Invitrogen, Milan, Italy), and stored at 80C for
subsequent RNA extraction.
GSH and GSSG analysis
High-performance capillary electrophoresis was used to
analyze the levels of glutathione (GSH) and glutathione
disulphide (GSSG) in plasma samples according to Raggi
et al.41 and Kong et al.42 An Agilent 3D CE Instrument
Table 2. Composition of OXI-3 (*), containing tocotrienols and tocopherols in the enantiomerically pure natural form.
Total tocotrienols and tocopherol minimum 250 mg/g (25%)
Isomeric composition of tocotrienolsComposition Range Typical value
Total D-Tocotrienols in the mix Min. 190mg/g 197.5mg/g D-a-Tocotrienol 55–70mg
Total D-Tocopherol in the mix Min. 51mg/g 59mg/g D-b-Tocotrienol >7.5mg
D-c-Tocotrienol 102.5–120mg
D-d-Tocotrienol 27.5–35mg
Note: (*) OXI-3 was developed by Ambrosialab, University of Ferrara, Italy.
Table 1. Subject characteristics.
Healthy control subjects FRDA subjects
No. Gender
Age at time
of study
FXN mRNA
expression
(std dev) No. Gender
Age at time
of study
Age of
disease onset
Number of
GAA repeats in the
less expanded allele
Total ICARS
SCORE
FXN mRNA
expression
(std dev)
1 F 19 1 0.11 1 F 13 9 830 16 0.1 0.01
2 M 19 1.25 0.23 2 M 29 16 360 29 0.16 0.02
3 M 19 2.35 0.49 3 M 24 11 625 59 0.17 0.03
4 F 19 0.9 0.15 4 F 18 8 621 10 0.26 0.02
5 F 19 1.24 0.37 5 F 27 3 560 39 0.17 0.02
6 F 26 1.24 0.06 6 M 23 8 760 67 0.17 0.05
7 F 23 1.23 0.06 7 F 16 12 600 19 0.3 0.01
Note: FXN mRNA expression was arbitrarily set to 1 in control subject #1, then all FXN mRNA expression values were referred to that sample.
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(Palo Alto, Ca) electrophoresis system with a DAD detector
read the samples at 200 nm.
Samples were deproteinized with acetonitrile, then
analyzed with transient pseudo-isotachophoresis. An
uncoated fused silica capillary (20 cm 75 mm internal
diameter) was used. Runs were carried out with 10 kV sep-
aration voltage, using 300 mM phosphate buffer (pH 7.4).
Samples were pressure injected for 40 s, in order for the
sample length to reach 25% of the effective capillary
length, yielding a 15–20 fold increase in sensitivity.
Carbonyl group evaluation
Plasma sample preparation. Plasma albumin/IgG-
depletion was carried out following the protocol described
in Guidi et al.43 by using the Blue Albumin and IgG
Depletion kit (Sigma-Aldrich, France) according to the
manufacturer’s instructions. Samples were stored at
20C before use. The Bradford assay (Bio-Rad
Laboratories, Hercules, CA) was used to assess protein con-
centration of each sample.
Two-dimensional gel electrophoresis. Two-dimensional
polyacrylamide gel electrophoresis was performed under
the same conditions described previously.43 Briefly, protein
plasma samples were diluted in 125 lL of the lysis buffer
previously described,43 except that 0.2% of the appropriate
IPG buffer (GE Healthcare, USA) was used. At least three
samples were studied for each subject, in order to assess
biological and analytical variation. Immobilized non-linear
pH gradient strips (pH 4–7; 7 cm length IPG strips; GE
Healthcare, USA) were rehydrated at 16C with lysis
buffer containing 0.2% carrier ampholyte.
Isoelectrofocusing (IEF) was performed using the
EttanTM IPGphorTM system (GE Healthcare, USA) at 16C
following electrical conditions described previously.43 Before
the second-dimension run, the IPG strips were incubated
with two different equilibrating buffer solutions43 for 12
and 15min, respectively. The second-dimensionwas applied
on 9–16% polyacrylamide linear gradient gels at 10C. The
applied current was 40mA/gel and the gels were run until
the dye reached their lower end. The Coomassie gels were
stained with colloidal blue Coomassie G-250.
Derivatization of protein carbonyls and immunostaining
for DNP. Protein carbonyl analysis was assessed according
to the protocol described previously.43 In particular, after
DNPH staining and removal of excess dye,43 IPG strips
were used for the second-dimension separation. The
plasma proteins were then blotted into a PVDF membrane
as reported previously.44,45 According to Guidi et al.,43 the
protein carbonyls were detected incubating the PVDF
membrane with DNP/IgG primary antibody, and then
with a specific secondary antibody. Spot detection was car-
ried out using the Immobilon Western Chemiluminescent
AP substrate (Millipore) according to the manufacturer’s
instructions.
Image acquisition and analysis. Two-dimensional
Coomassie-stained gels and oxyblots were scanned using
an Epson expression 1680 PRO scanner; the acquired
images were analyzed using ImageMaster 2D Platinum
6.0 software (GE Healthcare, USA). For each subject, a min-
imum of three technical replicates were performed and
only the spots present in all the replicates were taken into
consideration for subsequent analysis. Coomassie gels
were used to normalize the intensity of carbonylated
spots, as previously reported.43 The normalized oxyblots
obtained from all patients before therapy were then com-
pared with the oxyblots obtained from patients after ther-
apy (twomonths and one year) and from healthy controls.
Oxygen radical absorbance capacity assay
Total antioxidant activity was evaluated by the ORAC
assay according to a method modified by us (see Pessina
et al.,46 and references quoted therein). In the final reaction
mixture (0.2mL total volume), plasma samples were initial-
ly mixed with fluorescein sodium salt (85 nM). The reaction
was started by the addition of 2,20-azobis(2-amidino-pro-
pane) dihydrochloride (AAPH), a free radical initiator tar-
geting the fluorescein. A calibration curve (10, 20, 30, 40,
50lM) was made with a standard solution of Trolox, a
derivative of vitamin E. The fluorescence intensity was
monitored at 37C, every 5min for 30min using
Fluoroskan Ascent FLVR (Thermo Fisher Scientific, Inc.
Waltham, MA) (excitation at 485 nm, emission at 538 nm).
The ORAC values were obtained by subtracting the areas
under the quenching curve of fluorescein of the blank from
that of each evaluation. ORAC values were referred as
Trolox equivalents (TE), pH¼ 7.4. The experiments were
carried out in triplicate.
Lipidomic analysis
Lipidomic analysis was performed as reported previous-
ly.47 Briefly, plasma was separated from the whole blood
by centrifugation; erythrocytes were lysed and then centri-
fuged in order to obtain plasma membranes. The extraction
of phospholipids from red blood cell membranes was car-
ried out according to the method of Bligh and Dyer.48 The
total phospholipid fraction was then incubated with KOH/
MeOH solution (0.5M) for 10min at room temperature, and
fatty acid methyl esters were subsequently extracted with
n-hexane. All fatty acids and their isomers, separated by
gas chromatography, were identified by comparing them
with commercially available standard markers and with a
custom-made library of geometrical transMUFA and PUFA
obtained by thiyl radical-catalyzed reaction of naturally
occurring lipids.49 The amount of each fatty acid in red
blood cell membranes was expressed as percentages of
the total fatty acids identified; however, we reported only
the percentage of the main saturated and unsaturated res-
idues of phospholipids, along with some relevant meas-
ures, such as total saturated (SFA), total monounsaturated
(MUFA), and total polyunsaturated (PUFA n-3 and PUFA
n-6) residues, some indicative ratios, peroxidation Index
(PI)50 and unsaturation index (UI).50
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RNA separation and quality control
Total RNAwas obtained from the TrizolVR lysates according
to the manufacturer’s data sheet.51 RNA quality was
assessed as described previously.27 Briefly, the integrity of
RNA was confirmed by visualization of the 28S and 18S
band sharpness. For removal of genomic contaminating
DNA from RNA samples, an RNase-free deoxyribonucle-
ase I (DNase I) (Amplification Grade DNase I, Sigma,
St. Louis, Mo) treatment was performed. After treatment,
the absence of genomic DNAwas confirmed by evaluating
the expression of the HSP70 promoter using a couple of
specifically designed primers (Table S1). RNA concentra-
tion was evaluated by the Ultrospec 3000 spectrophotom-
eter (Pharmacia Biotech, Cambridge, England).
The RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas International Inc., Thermo Fisher, Burlington,
Ontario) was used to reverse transcribe equal amounts of
total RNA, according to the manufacturer’s data sheet.
Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was carried out in trip-
licate in a BioRad CFX96 real-time thermal cycler using the
SsoFastTM EvaGreenVR Supermix (Bio-Rad Laboratories,
Hercules, CA). Data were normalized to the housekeeping
genes Beta-Actin and GADPH. The primer sequences are
shown in Table S1. Primers were chosen with the help of the
PRIMER3 and AMPLIFY free software; whenever possible,
primers were designed so as to span an exon–exon junction
and they were obtained from Sigma-Genosys (Sigma-
Aldrich, St. Louis, Mo). Melting curve analysis followed
by agarose gel electrophoresis confirmed primer specificity
of PCR products. Data were analyzed with the 2DDCT
method,52 taking into account the efficiency of the real-
time PCR reaction53 which was between 95% and 105%.
The software package CFX ManagerTM (Bio-Rad
Laboratories) and qbase plus (http://www.biogazelle.
com/) were used for data calculation and statistical analy-
sis. Data were expressed as fold change with respect to
controls confidence interval.
Statistical analysis
The Shapiro–Wilk test was applied to assess normalcy of
the data. Depending on data distribution, non-parametric
(Kruskal–Wallis) or parametric (ANOVA) tests were used
for assessing statistical significance of results. Benjamini
and Hochberg false discovery rate (FDR) was applied to
correct P-values thus obtained. In order to compare two
sets of data, non-parametric (Wilcoxon-Mann-Whitney) or
parametric (two-tailed unpaired Student’s t) tests were
used. For all analysis, statistical significance was set
at P 0.05.
Results
Patient’s outcomes
No adverse side effects were observed after tocotrienol
treatment in the five patients with FRDA participating in
the study. They constituted a group with heterogeneous
clinical and genetic parameters. The neurological evalua-
tion, represented by the total score on the ICARS scale and
repeated after one year of treatment with tocotrienols,
showed a slightly worsening trend, in accordance with
the slow progressive trend generally observed for FRDA.
Among the instrumental examinations carried out, the
only one to demonstrate slight variations after one year of
treatment was the CMR study. In fact, the tests carried out
after one year of treatment showed a trend to a slight reduc-
tion in the extent of the myocardial mass characterized by
myocardial damage (positive to late enhancement), which
seemed to vary in a directly proportional relationship with
the cardiac mass, and more specifically with hypertrophy.
However, this figure was not statistically significant, most
likely due to the small number of patients studied (Table 3).
GSH and GSSG content of plasma
The mean GSH content of FRDA patients’ plasma was 2.5
 0.97 lM, a value not significantly different from that of
healthy controls. However, patients were found to have a
much higher (almost 9-fold) plasma concentration of GSSG,
and therefore their GSH/GSSG ratio was significantly
lower than the controls (Figure 1). The two-month tocotrie-
nol treatment caused a marked and significant increase of
the GSH/GSSG ratio, due to both an increase in GSH and
a decrease in GSSG content. It should be noted that
GSH/GSSG ratio, a useful indicator of the plasma oxidative
stress, is more sensible than the absolute amounts of GSH
and GSSG.54
Table 3. Cardiac magnetic resonance data of patients before and following one-year tocotrienol treatment (mean std dev) and relative statistical
significance (Student’s t test).
FE Vsx
(56–79%)
Vol TD Vsx
(47–92 mL/m2)
Vol TS Vsx
(14–39 mL/m2)
SV Vsx
(37–62 mL/m2)
Sp Td SIV
(5–8 mm)
Sp Td PP
(5–7 mm)
M Vsx
(70–113 g/m2)
M Lenha
(g/m2) % M Lenha
FRDA patients
at time 0
65.5612.18 62.20 16.08 22.60 13.58 39.60 4.93 12.0 3.67 10.0 3.46 65.86 17.19 12.36 9.50 14.78 8.05
FRDA patients
post-1 year
treatment
61.6610.49 57.26 29.93 29.02 18.50 43.04 13.90 12.20 3.96 8.80 2.17 60.54 12.78 7.50 5.82 13.62 7.58
P 0.090 0.677 0.137 0.619 0.883 0.493 0.311 0.497 0.852
Note: Values in brackets are the normal range for the healthy subjects. Normal values for Lenh are not reported.
aData relating only to four of the five patients.
FE: ejection fraction, Vsx left ventricle; VolTd: end-diastolic volume; VolTs: end-systolic volume; SV: stroke volume; Sp: thickness; SIV: interventricular septum; PP:
posterior wall; M: mass; Lenh: late enhancement (delayed wash out of intramyocardial gadolinium); % M: percentage of myocardial mass with positivity to late
enhancement.
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Carbonyl groups
Under the denomination “Carbonyl groups” fall the alde-
hyde and ketone groups which are caused by metal-
catalyzed oxidation of amino acidic residues under OS;
therefore, carbonyl groups are useful markers of protein
oxidation.55 For each patient, we obtained a pattern of
total plasma proteins stained in the 2-DE gels with
Coomassie and a pattern of oxidized proteins recognized
by Western blot analysis. For each plasma protein sample,
2D-oxyblots were compared with Coomassie-stained
2D-gels for normalization purpose and for evaluation of
the oxidation levels.
Figure 2(a) shows the representative images of the oxy-
blots obtained from the plasma; Figure 2(b) shows the cor-
responding Coomassie-stained gels indicating that the
same amount of protein had been separated in the different
gels. Experimental reproducibility was verified by per-
forming several replicates of random samples. The profiles
of the five FRDA patients were remarkably similar as for
the total amount of oxidized proteins as well as for the
presence of proteins with the same apparent molecular
weight. About 400 protein spots were identified in the
Coomassie-stained 2D gels, as shown in the representative
gel (Figure 2(b)). Overall, the pattern of protein spots was
similar in the plasma samples of normal subjects, of
FRDA patients before therapy and of the same patients
after two-month and one-year tocotrienol treatment.
However, the comparison of the 2D electrophoresis gels
from normal control subjects and from FRDA patients
showed that excess carbonyl groups are clearly present in
the patient samples; moreover, the decrease of carbonylated
proteins upon two-month tocotrienol treatment and their
almost complete clearance upon one-year therapy was
evident.
In Figure 2(a), six different spots in the oxyblot are
marked, which greatly decrease in carbonylation level
with tocotrienol treatment. The intensity of these carbony-
lated spots was expressed as the mean SD of normalized
percentage of oxyblot spot volumes, calculated according
to the formula reported in Guidi et al.43 and drawn in the
Figure 1. GSH/GSSG ratio in plasma derived from healthy control subjects
(CTR) and FRDA patients before (FRDA) and after two month (FRDA post-2
months) tocotrienol supplementation. Data are presented as MeanSD.
ANOVA (P¼ 0.0089) and two-tailed Student’s t-test were applied. Significance
was maintained after P value false discovery rate (FDR) correction. Significance:
(*) P< 0.05.
Figure 2. Representative images of two-dimensional electrophoresis gels and oxyblots of plasma from one healthy control subject (CTR) and one Friedreich ataxia
patient before (FRDA) and after two month (FRDA post-2 months) or one-year (FRDA post-1 year) tocotrienol supplementation. The pH range was 4 to 7. Panel (a)
Carbonylated proteins were detected by Western blot using a primary antibody directed against DNPH-derivatized carbonyl groups (see methods). Labeled spots
represent the spots which showed a higher variation in carbonylation level. Panel (b) Total proteins were visualized by colloidal blue Coomassie G-250 staining. The
Coomassie-stained gels correspond to the oxyblots shown in panel a. (A color version of this figure is available in the online journal.)
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histogram of Figure 3. The identification of the proteins that
are differentially carbonylated is currently being performed
by means of MALDI-TOF analysis.
The decrease in anti-DNP reactive proteins was already
significant following two-month tocotrienol treatment
(P¼ 0.0498) and even more marked following one-year
tocotrienol treatment (P¼ 0.0004). After one-year tocotrie-
nol, the amount of carbonylated proteins, though highly
reduced, was still higher in plasma from FRDA patients
than in controls (P¼ 0.04324).
Figure 3. Levels of plasma protein carbonylation in healthy control subjects (CTR) and Friedreich ataxia patients before (FRDA) and following two-month (FRDA post-2
months) or one-year (FRDA post-1 year) add-on tocotrienol supplementation. Values are expressed as MeansSD of percentage oxyblot spot volumes normalized to
the Coomassie-stained spot volumes (%V, where V¼ integration of OD over the spot area and where % V¼ V single spot/V total spots). Significance was evaluated by
ANOVA (P< 0.00001) and maintained after P value false discovery rate (FDR) correction. Stars show statistical significance for relevant two-tailed Student’s t test
comparisons: (*) P< 0.05; (**) P <0.01; (***) P <0.001.
Figure 4. Oxygen radical absorbance capacity (ORAC) was analyzed in plasma derived from healthy control subjects (CTR) and FRDA patients before (FRDA) and
after two-month (FRDA post-2 months) and one-year (FRDA post-1 year) tocotrienol supplementation. Data are expressed as lM Trolox/L (MeanSD). Significance
was evaluated by ANOVA (P¼ 0.0007) and maintained after P value false discovery rate (FDR) correction. Stars show statistical significance for relevant Student’s two-
tailed t test comparisons: (*) P< 0.05; (**) P< 0.01.
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Oxygen radical absorbance capacity
In Figure 4, the ORAC values of controls and of FRDA
patients are compared. Tocotrienol treatment for two-
months did not increase the plasma oxygen radical absor-
bance capacity of FRDA patients, whereas one-year-long
supplementation was able to increase significantly
(P¼ 0.0454) ORAC values.
Lipidomics
Lipidomic analysis was carried out on only four out of five
FRDA patients and on healthy controls; control values were
comparable with those of healthy subjects with mean age
(25 10 years) or younger.56 Although membrane fatty acid
composition is somehow tissue-specific, it was found that
erythrocyte membranes are representative of the fatty acid
composition of most body tissues.57,58
The complete analysis is reported in Table S2, while
Figure 5 shows some relevant results. In particular, patients
displayed an excess (P¼ 0.025) of the saturated lipid stearic
acid (18:0), which, remarkably, decreased to normal levels
as a consequence of the two-months tocotrienol treatment
(P¼ 0.044). However, the statistical significance of ANOVA
for stearic acid was not maintained after false discovery
rate correction. The increase of stearic acid could be due
to the de novo synthesis of saturated fatty acids, which is the
first step in the regeneration of the lipid pools after OS. Two
indices of inflammation were found to be increased in
FRDA patients, namely arachidonic acid (20:4), a precursor
of a number of inflammation mediators, which tends to
decrease towards normal levels with tocotrienol treatment
and the x6/x3 ratio, an index of the balance between the
prevalently inflammatory omega-6 pathway and the anti-
inflammatory omega-3 pathway.59 The arachidonic acid
content can be correlated with the inflammatory status
since, when released from the membranes, arachidonic
acid initiates the eicosanoid cascade.59 Worth nothing, the
peroxidation index was found to be similar in controls and
in FRDA patients. This value depends on the amount of
PUFA residues and reflects the propensity to peroxidation.
Gene expression of some antioxidant enzymes and
inflammation molecules
Gene expression was evaluated by qPCR in leukocyte
extracts, in order to study the expression of a number of
antioxidant enzymes not otherwise evaluable. The reaction
efficiency was between 0.95 and 1.05 for all genes and both
the melting curve and the gel electrophoresis showed that a
single product was amplified in the PCR, thus demonstrat-
ing that the primers had been correctly chosen. Figure 6
shows the results of the gene expression study of the fol-
lowing genes: Thioredoxin Reductase 1, (TXNRD1);
Nuclear Factor, Erythroid 2 like 2 (NRF-2); Superoxide
Dismutase-1 (SOD-1), Superoxide Dismutase-2 (SOD-2),
Figure 5. Relevant lipidomic parameters (MeanSD) from healthy control volunteers (CTR) and from FRDA patients before (FRDA) and after two month (FRDA post-2
months) tocotrienol supplementation. The content of individual fatty acids in erythrocyte membranes is expressed as percentages of the total fatty acids identified.
Significance was evaluated by ANOVA; significance was not maintained for stearic acid after P value false discovery rate (FDR) correction. Stars show statistical
significance for relevant Student’s two-tailed t test comparisons: (*) P< 0.05; (**) P< 0.01.
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Catalase (CAT), Glutathione Peroxidase-1 (GPX-1),
Glutathione Reductase (GSR), Hepcidin (HAMP), Tumor
Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6).
The mRNA expression of TNXRD1, a selenoprotein thi-
oredoxin reductase, and of Nrf2, the major regulator of cel-
lular responses to OS, was significantly upregulated in
FRDA subjects, independently of tocotrienol treatment.
The gene expression analysis of the antioxidant enzymes
examined does not show significant variations in the com-
parison between control and FRDA subjects, although a
trend for an increased expression in SOD-1 and GSR can
be perceived. Following tocotrienol supplementation, a
trend of decreased mRNA expression was observed.
Moreover, we evaluated the gene expression of GST
(Glutathione S-Transferase), which may be expressed inde-
pendently of Nrf2 activation. Data (not shown) do not show
any significant difference between groups.
The expression of HAMP, a peptide hormone that regu-
lates iron homeostasis, was increased in FRDA patients.
Such increase was significantly higher after two month-
tocotrienol supplementation. The expression of two inflam-
matory genes, TNF-a and IL-6, was increased in FRDA
patients compared to controls; such increase was less
enhanced in two-month tocotrienol supplemented patients.
Limitations
This study has several limitations, including that some
evaluations were carried out only for the two-month
intermediate time, since a freezer failure destroyed some
samples obtained at time 12months, and that this was a
pilot study, involving only a small number of patients
(N¼ 5). However, it is worth noting that other studies
involving the evaluation of therapies in Friedreich’s
ataxia had comparable sample size.60 Moreover, in accor-
dance with other results, gene expression data support the
involvement of oxidative stress and inflammation in FRDA
patients and the positive effects of tocotrienol supplemen-
tation, but, due to the insufficient amount of the PBMCs we
could recover, we were not able to confirm these results by
protein expression analysis. In any case, the ensuing dis-
cussion is meant to show that the present study provided
new information that can be valuable for the scientific
community.
Discussion
Owing to the severe disruption of Fe-S cluster assembly in
key mitochondrial enzymes caused by frataxin deficiency,
there is little doubt that significant levels of ROS are gen-
erated in FRDA patient’s cells during mitochondrial activ-
ity, damaging key cellular structures and activities and
causing apoptosis in the more metabolically active cells,
such as neurons and cardiomyocytes. This undoubtedly
qualifies FRDA as an OS-related disease9 and suggests
that counteracting OS generation or OS-induced damages
would rescue sensitive tissues.61
Figure 6. Messenger RNA expression of antioxidant and inflammation genes in mononuclear white blood cell extracts from healthy control subjects (CTR) and FRDA
patients before (FRDA) and after (FRDA Post-2 Months) two months of tocotrienol by qPCR. Thioredoxin Reductase 1, (TNXRD1); Nuclear Factor, Erythroid 2 like 2
(NRF-2); Superoxide Dismutase-1 (SOD-1); Superoxide Dismutase-2 (SOD-2); Catalase (CAT); Glutathione Peroxidase (GPX-1); Glutathione Reductase (GSR);
Hepcidin (HAMP); Tumor Necrosis Factor-alpha (TNF-a); Interleukin-6 (IL-6). Data were normalized with two housekeeping genes, Beta-Actin and GAPDH. For each
gene, the normalized expression value of CTR was set to 1, and the other gene expression data were reported to that sample. Data are expressed as fold change
 confidence interval (CI). Parametric analysis was applied for all genes except for GPX-1, HAMP, and TNF-a, which were analyzed by non-parametric methods.
Significance was maintained after P value FDR correction, except for SOD-1. Stars show statistical significance for relevant comparisons: (*) P<0.05; (**) P< 0.01;
(***) P< 0.001.
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In order to evaluate the efficacy of antioxidant treat-
ments, the appropriate OS markers should be assessed
taking into account the peculiarities of FRDA pathobiology.
For instance, it has been reported that FRDA patients exhib-
it increased levels of plasma malondialdehyde,9 a highly
reactive compound generated by radical attack to polyun-
saturated fatty acids, while other markers of radical
damage, such as urinary 8-oxo-20-deoxyguanosine
(8-oxodG), were not consistently found.10 Similarly, since
the Nrf2 system appears to be impaired in FRDA,16 it
should not come as a surprise that OS failed to increase
the expression of antioxidant genes regulated by Nrf2,
whereas TNXRD1, which is upstream rather than down-
stream from Nrf2,62 and Nrf2 itself, is upregulated in
FRDA patients, even if they are treated with idebenone.
Discussing into the detail the individual data,
• The GSH/GSSG ratio, a relevant index of ROS detox-
ifying ability, was found to be markedly reduced in
the plasma of FRDA patients, but tended to be
normal values following the two-month treatment
with tocotrienols.
• Carbonyl groups, an index of OS-induced damage to
cell proteins, were markedly increased in FRDA
patients compared to healthy subjects, but displayed
a reduction by about 30% after two-month tocotrienol
treatment and by about 66% following one-year toco-
trienol supplementation. Notably, oxidation did not
appear to affect all proteins at the same extent, and it
would be of interest to identify these through further
analyses.
• Plasmatic ORAC displayed a reduction in FRDA
patients and was restored to normality only follow-
ing a one-year tocotrienol supplementation, suggest-
ing that this is not a very sensitive indicator of the OS
affecting the whole organism.
• Changes in membrane fatty acid composition, when
examined by functional lipidomics tools,63 were sug-
gestive of the presence of both OS and inflammation
in FRDA patients, because of the combined increase
in stearic acid, arachidonic acid, and the x6/x3 ratio;
notably, stearic acid is related to the production of
TNF-alpha, an inflammation marker.64 The two-
month tocotrienol supplementation favored the
decrease of these indices. It can also be hypothesized
that the patients’ lipid membrane profile would have
displayed a further normalization, should it be eval-
uated following a longer anti-oxidant treatment. It is
worth mentioning that no dietary treatment of
patients regarding the essential fatty acid (EFA)
intake was made during treatment, thus suggesting
that the observed specific fatty acid changes can be
likely ascribed to the antioxidant supplementation.
Moreover, our results suggest further investigations
on the association of tocotrienol supplementation
with a diet containing a specific EFA balance.
• Gene expression of antioxidant enzymes, as already
pointed out, can be understood by taking into
account the inability of chronically stressed cells to
activate the Nrf2 driven response,16 which controls
the level of SOD1, SOD2, catalase, GPX1, and GSR,
among others. On the other hand, TXNRD1 and Nrf2
were upregulated in FRDA patients.
Notwithstanding the limited number of subjects in this
study, the data examined so far clearly show that (i) FRDA
patients are affected by OS, despite long-term idebenone
treatment: a result which accounts for the limited efficacy
of idebenone in counteracting the progression of the dis-
ease; (ii) add-on tocotrienol treatment considerably reduces
OS biomarkers even when administered at very low doses
and for a relatively short time (twomonths); moreover, data
suggest that tocotrienol supplementation protracted for one
year or longer may further decrease the OS biomarkers.
Since we only evaluated the add-on treatment, we are
unable to make any statement about the presence or
absence of synergistic effects. On the clinical side, our
results suggest that the combined treatment with idebe-
none and low tocotrienol doses may be beneficial. In
effect, one should bear in mind that the efficacy of idebe-
none in delaying FRDA progression is supported by a rel-
atively weak clinical evidence65 and has not been
previously investigated using OS biomarker studies. Our
data support the finding that FRDA patients show
increased inflammatory biomarkers, in accordance with
the observation by Nachum et al.,66 who described the tran-
scriptional upregulation of inflammatory innate immune
response genes. This conclusion is based on the functional
lipidomic analysis and on the upregulation of two cytokine
mRNAs, TNF-a and IL-6; these indices were less pro-
nounced following the two-month tocotrienol supplemen-
tation. Although we unfortunately were unable to assess
the data relative to the one-year tocotrienol treatment, this
study does show clear relationship between OS and
inflammation.
Finally, this study examined for the first time the expres-
sion of HAMP mRNA in FRDA PBMCs. Compared to con-
trols, HAMP gene expression showed a trend towards
increase, which became highly significant after the two
month-tocotrienol supplementation. HAMP is a key regu-
lator of iron homeostasis, both at the systemic and at the cell
level67 and may be involved in the iron dysregulation
occurring in cells of FRDA patients.68 Here, the increase
of HAMP expression should be viewed at the light of its
upregulation in inflammation, where HAMP plays a
double role in preserving the macrophage iron pool and
in downregulating the levels of TNF-a and IL-6 expres-
sion.69 An antioxidant response element has been identified
in the promoter of the murine HAMP gene,70 suggesting
that HAMP might be a pivot in the Nrf2-regulated battery
of genes acting in OS responses, iron toxicity control, and
anti-inflammatory activities. The increase of HAMP expres-
sion following the two-months tocotrienol administration
can be tentatively explained by a role for tocotrienols as
Nrf2 activators, in a manner similar to that of Vitamins A
and C and small polyphenols71,72 or by their ability to
decrease OS, with consequent reduction of the Nrf2 anergy.
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